ISPOR

Implantica publishes Interim Report January - September 2023 (Q3)

Retrieved on: 
Wednesday, November 22, 2023
ID, Mary, mother of Jesus, Corporate Affairs, Safety, Food, CFO, Saint Mary's Hospital, GERD, Investment, EFS, Surgeon, Nissen fundoplication, Learning, Vienna General Hospital, Patient, CET, Congress, FDA, ARB, NHS, AFS, Food and Drug Administration, Usability, IPAC, Certification, ISPOR, Health, Hospital, PMA, Hernia, Pharmaceutical industry, Medical device

The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.

Key Points: 
  • The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.
  • The IPAC review process is a key step for NHS hospitals to adopt our technology with strong international influence.
  • Implantica will hold a teleconference on 22 November 2023 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer).
  • The information was submitted for publication, through the agency of the contact person set out above, at 2023-11-22 08:00 CET.

New Research Sheds Light on Mediators of Improved Outcomes in Dario Users

Retrieved on: 
Tuesday, November 21, 2023
Digital health, Diabetes Technology Society, ISPOR, Adherence (medicine), Sanofi, Research, Behavior, DTS, Medicine, Birth control, Medical imaging, Glycated hemoglobin

NEW YORK, Nov. 21, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users.

Key Points: 
  • NEW YORK, Nov. 21, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new analyses recently presented by Sanofi U.S. demonstrating two mediators associated with improved clinical and economic in Dario users.
  • Dario users saw an overall clinically significant reduction in HbA1c and an associated 10.6% improvement in medication adherence.
  • The new research helps explain the results of a previously reported study on reductions in HbA1c, because medication adherence is one behavioral component of self-care needed to achieve improved clinical outcomes.
  • These results showed that meaningful engagement activities and medication adherence are both important contributors to the better outcomes in Dario users."

Implantica's RefluxStop™ health economic research, showing superior cost-effectiveness, has received top-recognition at ISPOR, the world's leading European Health-Economics Conference

Retrieved on: 
Thursday, November 16, 2023
International Society, Research, Pharmacoeconomics, GERD, Patient, CET, University of York, HTA, Certification, Abstract, ISPOR, Systematic review, Health technology assessment, Medical device, Payment

The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options.

Key Points: 
  • The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options.
  • The Quality-of-Life analysis of GERD patients clearly showed that surgical management of GERD leads to a better Quality-of-Life than disease management through medication.
  • ISPOR is globally recognized as the leading scientific and educational organization for health economics and outcomes research (HEOR) and its use in the healthcare decision-making process.
  • To present such impactful economic data and be selected in the "Top 5% poster category" at ISPOR is a true honor for Implantica.

OPEN Health Presenting Innovative Research on Capitalizing Data for Patient Access at ISPOR Europe

Retrieved on: 
Thursday, November 9, 2023
Science, FDA, Policy, Human, OPEN, Health, ISPOR, Research, HTA, EMA, Master of Science, Patient-centered outcomes, Meta-analysis, Management, Medical device, EU

London, UK – November 9, 2023 – OPEN Health , a preeminent global provider of consulting , HEOR and market access , patient engagement , and scientific and creative communications services, will be presenting innovative research at the upcoming ISPOR Europe conference in Copenhagen, Denmark.

Key Points: 
  • London, UK – November 9, 2023 – OPEN Health , a preeminent global provider of consulting , HEOR and market access , patient engagement , and scientific and creative communications services, will be presenting innovative research at the upcoming ISPOR Europe conference in Copenhagen, Denmark.
  • Key themes of OPEN Health’s research presented this year are patient preference, advanced modeling methodologies, and HTA policy changes.
  • Dr. Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, said: “I am extremely proud to see the research we do at OPEN Health being presented by our scientific experts at the ISPOR EU conference in Copenhagen.
  • To learn more about our presence at ISPOR Europe, visit our website or meet the OPEN Health team at booth #C2-012 in Copenhagen.

Suvoda eCOA Earns High Marks in Patient Usability Study

Retrieved on: 
Thursday, November 9, 2023
FDA, Smartphone, IRT, Reading, American Opportunity Tax Credit, Data collection, Certification, Doctor of Philosophy, CNS, Patient, ISPOR, Software, Nature, Usability, PRO, Central nervous system, Medical device, Nursing

PHILADELPHIA, Nov. 9, 2023 /PRNewswire/ -- Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.

Key Points: 
  • The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
  • Suvoda announced the general availability of its eCOA product in May 2023 to address the difficulties and delays associated with traditional eCOA products.
  • And, because Suvoda eCOA, IRT, and eConsent are delivered on a single platform, study teams benefit from improved data integrity.
  • "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."

Suvoda eCOA Earns High Marks in Patient Usability Study

Retrieved on: 
Thursday, November 9, 2023
FDA, Smartphone, IRT, Reading, American Opportunity Tax Credit, Data collection, Certification, Doctor of Philosophy, CNS, Patient, ISPOR, Software, Nature, Usability, PRO, Central nervous system, Medical device, Nursing

PHILADELPHIA, Nov. 9, 2023 /PRNewswire/ -- Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.

Key Points: 
  • The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
  • Suvoda announced the general availability of its eCOA product in May 2023 to address the difficulties and delays associated with traditional eCOA products.
  • And, because Suvoda eCOA, IRT, and eConsent are delivered on a single platform, study teams benefit from improved data integrity.
  • "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."

New Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 Diabetes

Retrieved on: 
Tuesday, October 17, 2023
ISPOR, Type 2 diabetes, Bias, Dario Alessi, Academy of Managed Care Pharmacy, Medicaid, Digital health, HEDIS, Diabetes, Patient, Medicare, Sanofi, Research, Pharmaceutical industry, Health insurance, Dietary supplement, Nexus, Glycated hemoglobin

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research presented by Sanofi U.S. at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus ("AMCP-Nexus"), demonstrating a 36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes.

Key Points: 
  • New data presented by Sanofi U.S. at AMCP-Nexus examined matched Dario users and non-users with type 2 diabetes to understand the impact of Dario's digital health solution.
  • A panel of independent judges awarded the research the AMCP-Nexus Gold ribbon award after assessing for relevance, originality, quality, bias and clarity.
  • "Our research collaboration with Sanofi U.S. continues to yield strong results demonstrating the real, measurable value of digital health for payers.
  • The research showed 9% more Dario users achieved HbA1c below 8% (control) compared to non-users after 12 months and 13% less Dario users stayed above 9% (poor control).

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Retrieved on: 
Wednesday, October 11, 2023
ISPOR, Vaccine, CDT, Central Time Zone, Tropical medicine, Disease, Donald Mackay Medal, International Society, CHIKV, Pharmacoeconomics, Cost, VLA, Systematic, European Congress of Mathematics, Society, IDSA, Climate, Infectious Diseases Society of America, CEST, Meta-analysis, Vaccination, Pulse vaccination strategy, Pregnancy, Disability-adjusted life year, EDT, Patient, Central European Summer Time, Euronext Paris, Global Burden of Disease Study, Valneva SE, Saint-Herblain, Pharmaceutical industry, Immunodeficiency, Chikungunya, Hygiene

Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.

Key Points: 
  • Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.
  • At IDWeek, the annual meeting of the Infectious Diseases Society of America (IDSA), Valneva will support the roundtable discussion “Chikungunya is an Increasing Global Threat: The Need for Better Protection” taking place on October 14, 2023 at 6:00 pm Eastern Daylight Time (EDT) in Boston, Massachusetts.
  • At the American Society of Tropical Medicine and Hygiene (ASTMH) 2023 Annual Meeting in Chicago, Illinois, Valneva will hold two chikungunya presentations on October 20, 2023 at 11:00 am and 12:15 pm Central Daylight Time (CDT).
  • At the International Society of Vaccines Annual Congress taking place in Lausanne, Switzerland Valneva will present on chikungunya on October 24, 2023 at 09:45 am Central European Summer Time (CEST).

Innovative Medicines Provide Greater Value to Patients and Society than Previously Calculated

Retrieved on: 
Wednesday, September 6, 2023
Institute for Clinical and Economic Review, Insurance, CMS, CEA, ISPOR, Quality of life, Atorvastatin, Medicine, Rivaroxaban, IRA, Element, Government, Medicare, Inflation, Patient safety, Hospital, Patient, Animation, ICER, Federation, Inflation Reduction Act of 2022, Pharmaceutical industry, Health insurance

WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- A new report released today by the nonprofit group No Patient Left Behind revealed critical flaws in a key metric used by U.S. insurance companies and foreign governments to determine whether to cover prescribed treatments at low out-of-pocket costs. The report found that the methodology used by the Institute for Clinical and Economic Review (ICER) for analyzing the cost-effectiveness of drugs has been incorrectly claiming a number of medications offer insufficient value to patients and society.

Key Points: 
  • “When prices accurately reflect value to society, they encourage innovation that benefits patients and their families the most.
  • Traditional CEA also fails to account for the greater value that sicker patients might receive from a drug as compared to healthier patients.
  • Yet that quantifiable value doesn’t factor into how ICER or others practicing traditional cost-effectiveness math calculate the value of medicines when they first launch.
  • Payors have a responsibility to now pass along that value to patients without burdening them with high out-of-pocket costs."

Biodesix Announces Second Quarter 2023 Results and Highlights

Retrieved on: 
Monday, August 7, 2023
Oncology, Medical Devices, Health, Health Technology, Research, Science, Beth Israel Deaconess Medical Center, CMS, Marketing, ISPOR, COVID-19, American Society of Clinical Oncology, Medication, ORACLE, Completeness, NSCLC, COVID, Lung cancer, COVID-19 testing, Test management, Tulane University, ASCO, Medicare, Publication, Patient, International Society, Webcast, Einstein Healthcare Network, Growth, Society, Pharmaceutical industry, Medical imaging, Nursing, Medical device

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update
    “I am very pleased to announce another record-setting quarter from our core lung diagnostics,” said Scott Hutton, President and Chief Executive Officer.
  • All board members, all Section 16 officers, and additional members of the Biodesix leadership team participated in the round raising $27.5 million in equity funding to further support our growth.
  • We also maintained strong cost discipline, with sustainable and improving gross margins to 73% from 65%, and reducing our Operating Expense excluding direct costs and expenses by $2.7 million, all versus first quarter 2023.
  • The Company reaffirms our 2023 financial outlook and expects to generate between $52 million and $55 million in total revenue in 2023.